Ensiklopedia Dunia

Tikagrelor
Data klinis
Nama dagang	Briclot, Brilinta, Brilique, Clotaire, Ticage, dll
Nama lain	AZD-6140
AHFS/Drugs.com	monograph
MedlinePlus	a611050
License data	US DailyMed: Ticagrelor;
Kategori; kehamilan	AU: B1 ; ;
Rute; pemberian	Oral
Kode ATC	B01AC24 (WHO) ;
Status hukum
Status hukum	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ;
Data farmakokinetika
Bioavailabilitas	36%
Pengikatan protein	>99.7%
Metabolisme	Hati (CYP3A4)
Waktu paruh eliminasi	7 jam (tikagrelor), 8.5 jam metabolit aktif AR-C124910XX)
Ekskresi	Saluran empedu
Pengenal
	Nama IUPAC (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorofenil)siklopropilamino]-5-(propiltio)- 3H-[1,2,3]triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroksietoksi)siklopentana-1,2-diol;
Nomor CAS	274693-27-5 ;
PubChem CID	9871419;
IUPHAR/BPS	1765;
DrugBank	DB08816 ;
ChemSpider	8047109 ;
UNII	GLH0314RVC;
KEGG	D09017 ;
ChEMBL	ChEMBL398435 ;
CompTox Dashboard (EPA)	DTXSID901009337 ;
ECHA InfoCard	100.114.746
Data sifat kimia dan fisik
Rumus	C23H28F2N6O4S
Massa molar	522,57 g·mol−1
Model 3D (JSmol)	Gambar interaktif;
	SMILES CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1;
	InChI InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1 ; Key:OEKWJQXRCDYSHL-FNOIDJSQSA-N ;
	(what is this?) (verify)

Tikagrelor adalah obat yang digunakan untuk pencegahan strok, serangan jantung dan kejadian lain pada penderita sindrom koroner akut, yaitu masalah suplai darah di arteri koroner. Ia bertindak sebagai antiplatelet dengan memusuhi reseptor P2Y₁₂.^[6] Obat tersebut diproduksi oleh AstraZeneca.

Efek samping yang paling umum termasuk dispnea (kesulitan bernapas), pendarahan, dan peningkatan kadar asam urat dalam darah.^[5]

Obat ini disetujui untuk penggunaan medis di Uni Eropa pada bulan Desember 2010,^[5]^[7]^[8] dan di Amerika Serikat pada bulan Juli 2011.^[4]^[9]^[10]

Fungsi Klinis

Penggunaan tikagrelor diindikasikan untuk mencegah kejadian trombosis pada pasien dengan infark miokard. Berdasarkan studi PLATO, penggunaan tikagrelor pada pasien dengan sindrom koroner akut dapat menurunkan laju kematian tanpa peningkatan risiko perdarahan dibandingkan dengan klopidogrel.^[11]

Referensi

^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Diakses tanggal 13 May 2022.
^ "Ticalor; Blooms The Chemist Ticagrelor; Apo-Ticagrelor; Ticagrelor Arx (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Diakses tanggal 9 April 2023.
^ "Product monograph brand safety updates". Health Canada. February 2024. Diakses tanggal 24 March 2024.
^ ^a ^b "Brilinta- ticagrelor tablet". DailyMed. 10 August 2021. Diakses tanggal 19 May 2022.
^ ^a ^b ^c "Brilique EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 18 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Jacobson KA, Boeynaems JM (July 2010). "P2Y nucleotide receptors: promise of therapeutic applications". Drug Discovery Today. 15 (13–14): 570–578. doi:10.1016/j.drudis.2010.05.011. PMC 2920619. PMID 20594935.
^ "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.
^ European Public Assessment Report Possia
^ "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes" (Press release). U.S. Food and Drug Administration (FDA). 20 July 2011. Diarsipkan dari asli tanggal 12 January 2017.
^ "Drug Approval Package: Brilinta (ticagrelor) NDA #022433". U.S. Food and Drug Administration (FDA). 22 August 2011. Diakses tanggal 22 May 2021.
^ Salim, S (15 February 2015). "Ticagrelor, Harapan Baru Dalam Prevensi Sekunder Pada Pasien Infark Miokard". Kardioipdrscm.com.^{[pranala nonaktif permanen]}

[1] "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Diakses tanggal 13 May 2022.

[2] "Ticalor; Blooms The Chemist Ticagrelor; Apo-Ticagrelor; Ticagrelor Arx (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Diakses tanggal 9 April 2023.

[3] "Product monograph brand safety updates". Health Canada. February 2024. Diakses tanggal 24 March 2024.

[Brilinta_FDA_label-4] "Brilinta- ticagrelor tablet". DailyMed. 10 August 2021. Diakses tanggal 19 May 2022.

[Brilique_EPAR-5] "Brilique EPAR". European Medicines Agency. 17 September 2018. Diakses tanggal 18 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[6] Jacobson KA, Boeynaems JM (July 2010). "P2Y nucleotide receptors: promise of therapeutic applications". Drug Discovery Today. 15 (13–14): 570–578. doi:10.1016/j.drudis.2010.05.011. PMC 2920619. PMID 20594935.

[EPAR_Brilique-7] "Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.

[8] European Public Assessment Report Possia

[9] "FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes" (Press release). U.S. Food and Drug Administration (FDA). 20 July 2011. Diarsipkan dari asli tanggal 12 January 2017.

[10] "Drug Approval Package: Brilinta (ticagrelor) NDA #022433". U.S. Food and Drug Administration (FDA). 22 August 2011. Diakses tanggal 22 May 2021.

[11] Salim, S (15 February 2015). "Ticagrelor, Harapan Baru Dalam Prevensi Sekunder Pada Pasien Infark Miokard". Kardioipdrscm.com.^{[pranala nonaktif permanen]}

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

Ensiklopedia Dunia

Tikagrelor

Fungsi Klinis

Referensi

Beranda

Program Studi